Boehringer Ingelheim International Gmbh

Ablynx N.v.

Sanofi

Ludwig Institute for Cancer Research Limited

Other

Boehringer Ingelheim Gmbh

Viratherapeutics Gmbh

Evec Incorporated

Boehringer Ingelheim Pharma Gmbh & Co Kg

John Edward Park

Wolfgang J Rettig

Martin Lenter

Lloyd J Old

Toon Laeremans

Bruno Dombrecht

Cornelia Dorner-Ciossek

Gerald Beste

Rainer Zimmermann

Sigrid Cornelis

Ann Brigé

Stefan Hoerer

Heidi Rommelaere

Jo Vercammen

Lothar Kussmaul

Eric Lorent

Klaus Erb

Melanie Rieger

Bernd Weigle

Timothy Soos

Norbert Hauel

Sanjaya Singh

Keith Allen Canada

Alisa K Waterman

Tobias Litzenburger

Guido Wollmann

Joanne Van Ryn

Ulrich Kunz

Philipp Mueller

Patrik Erlmann

Katharina Zimmermann

Pascal Merchiers

Tobias Friederike Nolden

Matthias Grauert

Armin Heckel

Georg Dahmann

Stefan Peters

Jose William Saldanha

Gerald Juergen Roth

Joerg Kley

Raymond A Firestone

Thorsten Lehmann-Lintz

Pilar Garin-Chesa

Trixi Brandl

Juergen Mack

Pascal Gerard Merchiers

Barbara Kistler

Kenzo Takada

Kantou Nakajima

Leila A Telan

Uwe Bamberger

Dietmar Leipert

Nveed Chaudhary

Olivier L&egrave;ger

Katharina Zimmerman

Gerald Jürgen Roth

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

Recombinant rhabdovirus encoding for CCL21

The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.

Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

Methods of treating asthma with polypeptides targeting IL-13 and TSLP

Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

The present invention relates to the use of indolinones of general formula 

Medicaments for the treatment or prevention of fibrotic diseases

The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

A-beta binding polypeptides

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds

Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.

Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same

Nucleic acid molecules encoding A-beta binding polypeptides

Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds

The invention involves dimeric forms of the protein known as fibroblast activation protein alpha, or 'FAP&#x3b1;' and its uses.

Isolated proteins containing portions of FAP&#x3b1; and other proteins

The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.

FAP-activated anti-tumour compounds

Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.

FAP&agr;-specific antibody with improved producibility

Growing community of inventors

Warthausen, Germany

John Edward Park